ATE328008T1 - Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen - Google Patents

Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen

Info

Publication number
ATE328008T1
ATE328008T1 AT99921513T AT99921513T ATE328008T1 AT E328008 T1 ATE328008 T1 AT E328008T1 AT 99921513 T AT99921513 T AT 99921513T AT 99921513 T AT99921513 T AT 99921513T AT E328008 T1 ATE328008 T1 AT E328008T1
Authority
AT
Austria
Prior art keywords
heparanase
specific molecular
molecular probe
research
medical applications
Prior art date
Application number
AT99921513T
Other languages
English (en)
Inventor
Iris Pecker
Israel Vlodavsky
Yael Friedman
Tuvia Perets
Original Assignee
Insight Biopharmaceuticals Ltd
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Biopharmaceuticals Ltd, Hadasit Med Res Service filed Critical Insight Biopharmaceuticals Ltd
Application granted granted Critical
Publication of ATE328008T1 publication Critical patent/ATE328008T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
AT99921513T 1998-05-01 1999-04-29 Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen ATE328008T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/071,739 US6177545B1 (en) 1997-09-02 1998-05-01 Heparanase specific molecular probes and their use in research and medical applications

Publications (1)

Publication Number Publication Date
ATE328008T1 true ATE328008T1 (de) 2006-06-15

Family

ID=22103268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921513T ATE328008T1 (de) 1998-05-01 1999-04-29 Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen

Country Status (11)

Country Link
US (6) US6177545B1 (de)
EP (2) EP1734133A2 (de)
JP (1) JP2002512533A (de)
AT (1) ATE328008T1 (de)
AU (1) AU754228B2 (de)
CA (1) CA2295323A1 (de)
DE (1) DE69931624T2 (de)
ES (1) ES2267266T3 (de)
IL (1) IL133265A0 (de)
NO (1) NO996229L (de)
WO (1) WO1999057153A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6562950B2 (en) * 1997-09-02 2003-05-13 Insight Strategy & Marketing Ltd. Heparanase activity neutralizing anti-heparanase monoclonal antibody
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
EP1157118A4 (de) * 1999-03-01 2002-07-17 Insight Strategy & Marketing POLYNUKLEOTID, DAS FüR EIN POLYPEPTID MIT HEPARANASE-AKTIVäT KODIERT, UND DESSEN EXPRESSION IN GENETISCH VERäNDERTEN ZELLEN
AU777343B2 (en) * 1999-06-25 2004-10-14 Insight Biopharmaceuticals Ltd. Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase
CZ20022147A3 (cs) * 1999-12-23 2002-09-11 Schering Aktiengesellschaft Polypeptid příbuzný humánní heparanáze, polynukleotid, který ho kóduje, a jejich použití
EP1356083A2 (de) 2000-09-15 2003-10-29 Reddy US Therapeutics, Inc. Verfahren und zusammensutzungen zur bestimmung von glycosidase
JP2005500977A (ja) * 2000-12-19 2005-01-13 インサイト ストラテジー アンド マーケティング リミテッド 細胞移植改良のための細胞外基質分解酵素の使用
US20040132123A1 (en) * 2001-05-09 2004-07-08 Oron Yacoby-Zeevi Methods and kits utilizing heparanase as a diagnostic marker for haemostatic disorders
EP1417304A4 (de) * 2001-07-13 2005-11-23 Imclone Systems Inc Verfahren und zusammensetzung zur hemmung der heparanaseaktivität
US20030036103A1 (en) * 2001-07-31 2003-02-20 Sivaram Pillarisetti Methods and compositions for diagnosis and treatment of vascular conditions
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
EP1547979A1 (de) * 2002-06-21 2005-06-29 Sanden Corporation Vorrichtung zur Herstellung von Mineralwasser
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
AU2003292772A1 (en) * 2002-12-26 2004-07-22 Nippon Shinyaku Co., Ltd. PROCESS FOR PRODUCING PNPase
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
DK2383295T3 (en) * 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
IL162276A0 (en) * 2004-06-01 2005-11-20 Hadasit Med Res Service Nucleic acid molecules as heparanase potent inhibitors, compositions and methods of use thereof
EP1869462B1 (de) * 2005-03-11 2013-05-08 Ciphergen Biosystems, Inc. Biomarker für ovarialkrebs und endometriumkrebs: hepcidin
EP1982722A1 (de) * 2007-04-16 2008-10-22 Gentium S.p.A. Verwendung von Oligotid zur Behandlung von Nierenerkrankungen
US20100248260A1 (en) * 2007-12-05 2010-09-30 Massachusetts Institute Of Technology Glycosaminoglycan-coated particles and uses thereof
CN101983051B (zh) * 2008-03-31 2013-04-24 株式会社资生堂 用于防止或改善皱纹的口服、注射、皮肤外用剂和美容方法
US8772414B2 (en) * 2008-09-16 2014-07-08 Dow Global Technologies Llc Polymeric compositions and foams, methods of making the same, and articles prepared from the same
WO2011067711A2 (en) * 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP3026122A1 (de) 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
US10349968B2 (en) * 2016-05-02 2019-07-16 Covidien Lp Devices, systems, and methods for establishing electrical and fluid connections to surgical instruments
CA3182945A1 (en) 2020-07-06 2022-01-13 Israel Vlodavsky Heparanase-neutralizing a54 monoclonal antibody

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US931129A (en) * 1904-03-30 1909-08-17 Henry La Casse Shaft-hanger.
US2295323A (en) * 1940-08-02 1942-09-08 Edwin H Armstrong Current limiting device
US4117841A (en) * 1977-02-07 1978-10-03 Anthony Perrotta Medicated bandage pocket
US4659581A (en) * 1981-09-16 1987-04-21 Takeda Chemical Industries, Ltd. Method of producing granular chemical seasoning of high specific volume and product
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
US5206223A (en) * 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5061689A (en) * 1986-12-24 1991-10-29 Bioderm, Inc. Zinc bacitracin containing wound dressing
US4937747A (en) * 1988-02-16 1990-06-26 Amoco Corporation Iterative disjoint cluster and discriminant function processing of formation log responses and other data
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
DE69028514T2 (de) * 1989-01-10 1997-02-20 Amrad Corp Ltd Leukämiehemmender faktor aus vieharten und seine verwendung zur verbesserung der implantation und der entwicklung von embryonalen zellen
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5571506A (en) * 1989-08-14 1996-11-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
KR927003090A (ko) * 1989-08-23 1992-12-17 하다사 메디칼 오르가니제이션 헤파린효소를 포함하는 상처 치유 약제
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
CA2083052A1 (en) * 1990-05-31 1991-12-01 Garth L. Nicolson Immunochemical localization of heparanase in mouse and human melanomas
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
JPH04187408A (ja) 1990-11-21 1992-07-06 Toyo Ink Mfg Co Ltd 熱可塑性樹脂ペレットの製造方法およびその装置
FR2669932B1 (fr) * 1990-12-03 1994-07-01 Sanofi Sa Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
US5714345A (en) * 1990-12-24 1998-02-03 Pharmaceutical Proteins Limited Increased expression of a gene by a second transferred mammary gland specific sequence transgenic
AU1228592A (en) * 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5300059A (en) 1991-11-19 1994-04-05 Hydro Slip Technologies Inc. Bloodbag and method of making same
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
WO1993018745A1 (en) 1992-03-23 1993-09-30 Geda International S.A. Use of antiviral coating for latex items such as condoms
FR2690162B1 (fr) * 1992-04-21 1995-08-04 Rhone Poulenc Rorer Sa Peptides ayant une activite de facteur d'echange du gdp, sequences d'acides nucleiques codant pour ces peptides, preparation et utilisation.
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
CA2136724A1 (en) * 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
WO1994006442A1 (en) * 1992-09-11 1994-03-31 The Regents Of The University Of California Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9225581D0 (en) * 1992-12-08 1993-01-27 Courtaulds Plc Wound dressings
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
US5565193A (en) 1993-08-05 1996-10-15 Procter & Gamble Hair styling compositions containing a silicone grafted polymer and low level of a volatile hydrocarbon solvent
US5739115A (en) * 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
CA2184688A1 (en) * 1994-03-09 1995-09-14 Pedro Antonio Prieto Transgenic animals producing oligosaccharides and glycoconjugates
US5997863A (en) * 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US5830759A (en) * 1994-08-18 1998-11-03 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US5600366A (en) * 1995-03-22 1997-02-04 Npb Partners, Ltd. Methods and apparatus for digital advertisement insertion in video programming
US5799276A (en) * 1995-11-07 1998-08-25 Accent Incorporated Knowledge-based speech recognition system and methods having frame length computed based upon estimated pitch period of vocalic intervals
US5859929A (en) * 1995-12-01 1999-01-12 United Parcel Service Of America, Inc. System for character preserving guidelines removal in optically scanned text
JP2000502611A (ja) 1995-12-21 2000-03-07 コントラ−シェアー ホールディングス リミテッド スクリュプレスヘッド
US5859660A (en) * 1996-02-29 1999-01-12 Perkins; Michael G. Non-seamless splicing of audio-video transport streams
US6314420B1 (en) * 1996-04-04 2001-11-06 Lycos, Inc. Collaborative/adaptive search engine
US6020931A (en) * 1996-04-25 2000-02-01 George S. Sheng Video composition and position system and media signal communication system
US5799311A (en) * 1996-05-08 1998-08-25 International Business Machines Corporation Method and system for generating a decision-tree classifier independent of system memory size
US5917830A (en) * 1996-10-18 1999-06-29 General Instrument Corporation Splicing compressed packetized digital video streams
US6348344B1 (en) * 1997-09-02 2002-02-19 Insight Strategy & Marketing Ltd. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US6562950B2 (en) * 1997-09-02 2003-05-13 Insight Strategy & Marketing Ltd. Heparanase activity neutralizing anti-heparanase monoclonal antibody
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
EP1032656A4 (de) 1997-10-28 2002-10-29 Univ Australian Isolierte nukleinsäuremoleküle, welche für endoglukuronidase aus säugetieren kodieret, sowie deren verwendungen
US6387643B1 (en) * 1998-02-24 2002-05-14 Pharmacia And Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
US6230151B1 (en) * 1998-04-16 2001-05-08 International Business Machines Corporation Parallel classification for data mining in a shared-memory multiprocessor system
US6307965B1 (en) * 1998-04-30 2001-10-23 International Business Machines Corporation System and method for detecting clusters of information
US20030236215A1 (en) * 1998-08-31 2003-12-25 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
US6226792B1 (en) * 1998-10-14 2001-05-01 Unisys Corporation Object management system supporting the use of application domain knowledge mapped to technology domain knowledge
EP1157118A4 (de) * 1999-03-01 2002-07-17 Insight Strategy & Marketing POLYNUKLEOTID, DAS FüR EIN POLYPEPTID MIT HEPARANASE-AKTIVäT KODIERT, UND DESSEN EXPRESSION IN GENETISCH VERäNDERTEN ZELLEN
JP3717420B2 (ja) * 2001-04-27 2005-11-16 シャープ株式会社 モバイルコンセント、電力供給ゲート装置、サーバ装置および電力利用管理システム
US20020194625A1 (en) * 2001-05-25 2002-12-19 Insight Strategy & Marketing Ltd. Transgenic animals expressing heparanase and its uses
WO2003053138A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Transgenic expression of glycogen synthase kinase 3 in muscle
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies

Also Published As

Publication number Publication date
US20020114801A1 (en) 2002-08-22
EP1073682A1 (de) 2001-02-07
EP1073682B1 (de) 2006-05-31
IL133265A0 (en) 2001-04-30
US6177545B1 (en) 2001-01-23
EP1734133A2 (de) 2006-12-20
DE69931624T2 (de) 2007-05-03
AU3870699A (en) 1999-11-23
ES2267266T3 (es) 2007-03-01
JP2002512533A (ja) 2002-04-23
EP1073682A4 (de) 2001-02-07
DE69931624D1 (de) 2006-07-06
US7790376B2 (en) 2010-09-07
US20020004585A1 (en) 2002-01-10
US6800441B2 (en) 2004-10-05
NO996229L (no) 2000-02-24
US20040146925A1 (en) 2004-07-29
US6986996B2 (en) 2006-01-17
WO1999057153A1 (en) 1999-11-11
US6531129B2 (en) 2003-03-11
AU754228B2 (en) 2002-11-07
US20020102619A1 (en) 2002-08-01
CA2295323A1 (en) 1999-11-11
NO996229D0 (no) 1999-12-15
US20040229834A1 (en) 2004-11-18
US7049407B2 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
DE69931624D1 (de) Heparanase-spezifische molekulare sonden sowie deren verwendung in forschung und medizinischen anwendungen
Fnlay Pharmacokinetics of terbinafine in the nail
DE60131177D1 (de) Abbaubare polyacetal-polymere
WO2004021882A3 (en) Measuring properties of an anatomical body
EP1426054A4 (de) Medizinische verwendung eines histon-deacetylase-hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
DE60228605D1 (de) Katheteranordnung zur arzneimittelabgabe mit aufblasbarem ballon
BR9506470B1 (pt) composiÇço adesiva sensÍvel À pressço e sistema de distribuiÇço transdÉrmica de droga.
ATE358505T1 (de) Beschichtete endovaskuläre vorrichtung
BRPI0519739A2 (pt) combinaÇço compreendendo um agente fornecendo um sinal, um material de implante e uma droga
ATE343969T1 (de) Beschichtete medizinische geräte
WO2004028570A3 (en) A method for treating severe tinnitus
ATE518011T1 (de) Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
WO1999055285A3 (en) Dilating and support apparatus with disease inhibitors and methods for use
ATE302029T1 (de) Beschichtete medizinische geräte und verfahren zur sterilisation
DE60332453D1 (de) Ambulante infusionsmembranpumpe
WO2001002050A3 (en) Method and system for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response
ATE307625T1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
PT973463E (pt) Dispositivo de proteccao da zona intravenosa
BR0309256A (pt) Sistemas de liberação responsivos à temperatura
DE60037657D1 (de) Infektionsmittel enthaltendes medizinisches gerät und verfahren zu ihrer darstellung
WO2003011215A3 (en) Method and system to determine revised dosage
ATE411342T1 (de) Scfv antikörper gegen krankheiten-assoziierte moleküle
ATE243487T1 (de) Medizinisches gerät zur internen hitzebehandlung und medikamentenverabreichung
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
SE9000207L (sv) Laekemedel samt anvaendningen av detsamma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties